Theriva Biologics, Inc. Common Stock TOVX 深 沪
等待开盘 11-26 09:30:00 美东时间
0.2388
+0.008
+3.42%
华盛通- 最 高0.245
- 今 开0.2325
- 成交量 154.66万股
- 最 低 0.2216
- 昨 收 0.2309
- 总市值 216.33万
- 52周最高 2.08
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 0.201
- 委 比 33.33%
- 总股本 905.92万
- 历史最高 37800.00
- 量 比 0.60
- 振 幅 10.13%
- 历史最低 0.201
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Theriva Biologics Q3 EPS $(0.45) Beats $(1.13) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.13) by 60.18 percent. This is a 93.39 percent increase over losses of $(6.81) per share from
11-12 21:14
Theriva Biologics Addresses Unusual NYSE Trading Activity; Confirms No New Developments Since VIRAGE Trial Data Presentation At ESMO 2025
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today
10-25 02:35
Theriva Biologics Provides Response to Unusual Market Action
<p>Theriva Biologics announced unusual trading activity in its common stock on the NYSE American on October 24, 2025, and released a press statement under Section 401(d) of the NYSE Company Guide. The company conducted inquiries and concluded no corrective actions are necessary. No material developments or undisclosed events were identified as reasons for the market action. However, on October 13, 2025, the company presented expanded data from it...
10-24 18:31
Theriva Biologics Secures $4M Via Immediate Exercise Of 7.36M Warrants At $0.54/Share; Offers Investors 14.72M New Warrants At Same Price
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced
10-16 20:15
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) rose sharply in pre-...
10-16 17:30
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
Theriva Biologics announced a warrant inducement agreement with existing institutional investors, allowing the immediate exercise of warrants to purchase up to 7,360,460 shares at $0.54 per share for ~$4.0 million in gross proceeds. Investors will receive new warrants for up to 14,720,920 shares, exercisable after shareholder approval, with a five-year term. The transaction is expected to close on Oct. 17, 2025, with proceeds用于working capital and...
10-16 12:11
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
Theriva Biologics announced that expanded data from the VIRAGE Phase 2b trial of VCN-01 will be presented at ESMO 2025, and interim safety and pharmacokinetic data for SYN-004 will be shared at IDWeek 2025. VCN-01, an oncolytic adenovirus, targets tumor cells and enhances chemotherapy access, while SYN-004 aims to protect the gut microbiome in HCT recipients. Both presentations highlight Theriva’s commitment to addressing high unmet needs in canc...
10-13 12:00
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Theriva Biologics will present next-generation cancer treatments, VCN-12 and VCN-01, showcasing enhanced antitumor effects and intracranial application potential at the 32nd ESGCT Congress in Seville, October 7-10, 2025.
10-06 12:00
Theriva Biologics Restructures, Cuts Workforce by 32%
Theriva Biologics ( ($TOVX) ) has issued an update. On September 28, 2025, Ther...
10-03 04:39
Theriva Biologics Cuts 32% Of Workforce In Restructuring To Focus On Cancer Drug Development And Regulatory Strategy; Expects Will Extend Its Cash Runway Into Q2 Of 2026
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics, Inc. (the "Company") approved a plan to resize and restructure the Company (the
10-03 04:04
